Get the Stockscreener App
1.0809
1.97%
0.0209
Evogene Ltd stock is traded at $1.0809, with a volume of 42,434.
It is up +1.97% in the last 24 hours and down -11.40% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.06
Open:
$1.05
24h Volume:
42,434
Relative Volume:
0.57
Market Cap:
$9.42M
Revenue:
$6.74M
Net Income/Loss:
$-14.74M
P/E Ratio:
-0.4806
EPS:
-2.2491
Net Cash Flow:
$-18.31M
1W Performance:
-4.77%
1M Performance:
-11.40%
6M Performance:
-2.62%
1Y Performance:
-25.97%
1-Day Range:
$1.05
$1.0955
1-Week Range:
$1.00
$1.14
52-Week Range:
$0.95
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.0809 | 9.24M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
What drives Evogene Ltd stock priceEarnings Volatility Patterns & Low Cost Market Strategies - earlytimes.in
Will Evogene Ltd. stock keep outperforming rivalsEarnings Performance Report & Accurate Technical Buy Alerts - BỘ NỘI VỤ
Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL (PR Newswire) - Aktiellt
Evogene shares climb 5% as cost reductions help deliver earnings beat - MSN
Evogene Ltd. Reports Strategic Shift and Financial Results - MSN
Evogene Ltd. Earnings Call: Strategic Shifts and Optimism - The Globe and Mail
Is Evogene Ltd. stock cheap compared to fundamentals - newser.com
Evogene Ltd. (NASDAQ:EVGN) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Evogene Ltd. stock hit record highs again2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Is Evogene Ltd. stock oversold or undervalued2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Evogene: Q3 Earnings Snapshot - Stamford Advocate
Evogene earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Evogene Q3 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Evogene(EVGN.US) Q3 2025 Earnings Conference - 富途牛牛
Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com India
Evogene shares rise 5% as cost-cutting measures drive earnings beat - Investing.com Nigeria
Evogene Reports Third Quarter 2025 Financial Results - The AI Journal
Evogene Reports Q3 2025 Financial Results Amid Strategic Shift - TipRanks
Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales - TradingView
Evogene shares rise 5% as cost-cutting measures drive earnings beat By Investing.com - Investing.com South Africa
Evogene : Q3 2025 Consolidated Financial Statements - MarketScreener
[6-K] Evogene Ltd. Current Report (Foreign Issuer) | EVGN SEC FilingForm 6-K - Stock Titan
Will Evogene Ltd. stock outperform international peers2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Evogene Ltd. stock maintain growth storyMarket Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
[EFFECT] Evogene Ltd. SEC Filing - Stock Titan
Is Evogene Ltd. stock a buy for dividend growthJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - newser.com
How strong is Evogene Ltd. stock revenue growthCEO Change & Free Community Consensus Stock Picks - newser.com
Evogene Ltd. stock prediction for this weekGDP Growth & Weekly Top Gainers Trade List - newser.com
What technical models suggest about Evogene Ltd.’s comeback2025 Performance Recap & Reliable Intraday Trade Plans - newser.com
What's Next: Evogene's Earnings Preview - Benzinga
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):